The neuraminidase inhibitors are the treatment of choice for influenza virus infection. Oseltamivir-resistant (OsR) strains of influenza A(H1N1)pdm09 are described, but the effect of higher dose oseltamivir on efficacy, safety and emergence of resistance has not been addressed in the developed setting in outpatients. The objectives of the study were to compare standard dose (SD) versus double dose (DD) oseltamivir regimens for frequency of detecting OsR influenza virus, clinical disease resolution, virological clearance and adverse events.
Methods
This was an unblinded randomized controlled trial of community-based patients with confirmed influenza. Participants were randomized to a 5-day regimen of either SD or DD oseltamivir.
Results
Of 52 participants (aged 4.8–54.8 years), 25 received SD and 27 DD oseltamivir. Clinical resolution did not differ by dosing regimen (P=0.43); neither did virological clearance differ for either influenza A (P=0.20) or B (P=0.70). Adverse events, predominantly gastrointestinal, were greater with DD than SD (P=0.04). One OsR strain was detected prior to treatment and two individuals developed OsR strains during treatment, one each on SD and DD. Those with OsR strains did not appear to have a different clinical course.
Conclusions
DD oseltamivir did not appear to provide a clinical or virological advantage, nor reduce the emergence of oseltamivir resistance, but our study was underpowered. Adverse events occurred more frequently on DD compared to SD oseltamivir.
References
1.
HurtA.C., HoH.T., BarrI.Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.Expert Rev Anti Infect Ther2006; 4: 795–805.
2.
KramarzP., MonnetD., NicollA., YilmazC., CiancioB.Use of oseltamivir in 12 European countries between 2002 and 2007–lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.Euro Surveill2009; 14: 19112.
3.
YangJ.R., LinY.C., HuangY.P.Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009.PLoS ONE2011; 6: e18177.
HurtA.C., DengY.M., ErnestJ.Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.Euro Surveill2011; 16: 19770.
7.
DharanN.J., GubarevaL.V., MeyerJ.J.Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.JAMA2009; 301: 1034–1041.
HarvalaH., GunsonR., SimmondsP.The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009.Euro Surveill2010; 15: 19536.
15.
TramontanaA.R., GeorgeB., HurtA.C.Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.Emerg Infect Dis2010; 16: 1068–1075.
16.
BrookesD.W., MiahS., LackenbyA., HartgrovesL., BarclayW.S.Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.J Antimicrob Chemother2011; 66: 466–470.
17.
HurtA.C., HolienJ.K., ParkerM.W., BarrI.G.Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.Drugs2009; 69: 2523–2531.
18.
JacksonH.C., RobertsN., WangZ.M., BelsheR.Management of influenza: use of new antivirals and resistance in perspective.Clin Drug Investig2000; 20: 447–454.
19.
KisoM., MitamuraK., Sakai-TagawaY.Resistant influenza A viruses in children treated with oseltamivir: descriptive study.Lancet2004; 364: 759–765.
20.
TamuraD., SugayaN., OzawaM.Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.Clin Infect Dis2011; 52: 432–437.
21.
WhitleyR.J., HaydenF.G., ReisingerK.S.Oral oseltamivir treatment of influenza in children.Pediatr Infect Dis J2001; 20: 127–133.
22.
WardP., SmallI., SmithJ., SuterP., DutkowskiR.Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.J Antimicrob Chemother2005; 55: i5–i21.
23.
StephensonI., DemocratisJ., LackenbyA.Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.Clin Infect Dis2009; 48: 389–396.
24.
TaylorW.R., ThinhB.N., AnhG.T.Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.PLoS ONE2008; 3: e3410.
25.
MooreC., GalianoM., LackenbyA.Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.J Infect Dis2011; 203: 18–24.
26.
QuachC., NewbyD., DaoustG., RubinE., McDonaldJ.QuickVue influenza test for rapid detection of influenza A and B viruses in a pediatric population.Clin Diagn Lab Immunol2002; 9: 925–926.
UyekiT.M., PrasadR., VukotichC.Low sensitivity of rapid diagnostic test for influenza.Clin Infect Dis2009; 48: e89–e92.
29.
RashidH., ShafiS., HaworthE.Value of rapid testing for influenza among Hajj pilgrims.Travel Med Infect Dis2007; 5: 310–313.
30.
RouleauI., CharestH., Douville-FradetM., SkowronskiD.M., De SerresG.Field performance of a rapid diagnostic test for influenza in an ambulatory setting.J Clin Microbiol2009; 47: 2699–2703.
WangB., DwyerD.E., BlythC.C.Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.Antiviral Res2010; 87: 16–21.
33.
HurtA.C., HardieK., WilsonN.J.Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.J Infect Dis2012; 206: 148–157.
34.
WangB., TaylorJ., RatnamohanM.Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.Euro Surveill2012; 17: 20210.
35.
StrongM., BurrowsJ., StedmanE., RedgraveP.Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom.Euro Surveill2010; 15: 19565.
Australian Government Department of Health.Pandemic (H1N1) 2009 influenza and oseltamivir resistance – 12 September 2011. Canberra, Australian Government Department of Health and Ageing, 2011. (Updated 6 October 2011. Accessed 5 April 2013.) Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-Influenza.
DixitR., KhandakerG., IlgoutzS., RashidH., BooyR.Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.Infect Disord Drug Targets2013; 13: 34–45.
44.
FarrarJ., SedyaningsihE.R., MalikM.S., SetiawatyV.Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial.BMJ2013; 346: f3039.
45.
LeeN., HuiD.S., ZuoZ.A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.Clin Infect Dis2013; 57: 1511–1519.
46.
SantosL., CorreiaV., GiriaM.Genetic and antiviral drug susceptibility profiles of pandemic A (H1N1) influenza virus circulating in Portugal.Options for the Control of Influenza VII. 3–7 September 2010, Hong Kong SAR, China. Paper O-851.
47.
RoussetD., Le GoffJ., Abou-JaoudeG.Emergence of successive mutations in the neuraminidase of the pandemic H1N1 virus respectively associated with oseltamivir resistance and reduced susceptibility to both oseltamivir and zanamivir under treatment with neuraminidase inhibitors.Options for the Control of Influenza VII. 3–7 September 2010, Hong Kong SAR, China. Poster P-198.
48.
van der VriesE., StelmaF.F., BoucherC.A.Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.N Engl J Med2010; 363: 1381–1382.
49.
NguyenH.T., FryA.M., LovelessP.A., KlimovA.I., GubarevaL.V.Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/ I223R mutation from a child after prolonged treatment with oseltamivir.Clin Infect Dis2010; 51: 983–984.
50.
HurtA.C., LeeR.T., LeangS.K.Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation.Euro Surveill2011; 16: 19884.
51.
HurtA.C., LeangS.K., SpeersD.J., BarrI.G., Maurer-StrohS.Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses.Emerg Infect Dis2012; 18: 109–112.
52.
HurtA.C., ChotpitayasunondhT., CoxN.J.Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.Lancet Infect Dis2012; 12: 240–248.
TakashitaE., EjimaM., ItohR.A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.Eurosurveill2014; 19: 20666.
55.
Centers for Disease Control and Prevention (CDC).Update: influenza activity - United States, 2009-10 season.MMWR Morb Mortal Wkly Rep2010; 59: 901–908.
TreanorJ.J., HaydenF.G., VroomanP.S.Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.JAMA2000; 283: 1016–1024.
58.
HaydenF.G., JenningsL., RobsonR.Oral oseltamivir in human experimental influenza B infection.Antivir Ther2000; 5: 205–213.
59.
HaydenF.G., TreanorJ.J., FritzR.S.Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.JAMA1999; 282: 1240–1246.
